Trial site
Rheuma Medicus Sp z o o
Warsaw, 02 118, PolandEU-13 widening countryNot linked to an institution yet
- 19running trials
- 12closed trials
The trials here
What the 32 trials at this site are about, from their registry records.
- Phase
- Phase 323 trials
- Phase 26 trials
- Phase 43 trials
- Status
- Completed12 trials
- Active, not recruiting11 trials
- Not yet recruiting4 trials
- Recruiting4 trials
- Suspended1 trial
- Lead sponsor
- Janssen Research & Development, LLC5 trials
- MoonLake Immunotherapeutics AG3 trials
- Novartis Pharmaceuticals3 trials
- Sun Pharmaceutical Industries Limited3 trials
- Alumis Inc2 trials
- and 14 more
Running trials
Not yet recruiting
A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Phase 3 Study to Evaluate the Efficacy and Safety of Subcutaneous CT-P13 in Patients with Moderately to Severely Active Rheumatoid Arthritis
2026-526538-15-00· Phase 3· Celltrion Inc.· Source
Not yet recruiting
A Trial of LAD603 in Patients with Systemic Lupus Erythematosus
2026-527200-24-00· Phase 2· Almirall S.A.· Source
Recruiting
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
NCT07286058· Phase 3· Takeda· Source
Not yet recruiting
A study to assess the safety and efficacy of different doses of ELV001 to treat active rheumatoid arthritis in patients with an inadequate response to methotrexate and tumor necrosis factor inhibition (START SYNERGY)
2025-524005-32-00· Phase 2· Elevara Medicines Limited· Source
Recruiting
A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
NCT07438496· Phase 3· Janssen Research & Development, LLC· Source
Not yet recruiting
A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with psoriatic arthritis (PsA)
2025-522471-28-00· Phase 3· MoonLake Immunotherapeutics AG· Source
Active, not recruiting
A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo and risankizumab (active reference arm) in participants aged 18 years and over with active psoriatic arthritis and antiTNFα inadequate response.
2024-516219-25-00· Phase 3· MoonLake Immunotherapeutics AG· Source
Active, not recruiting
A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo in participants aged 18 years and over with active psoriatic arthritis who are naive to biologic DMARDs
2024-516213-20-00· Phase 3· MoonLake Immunotherapeutics AG· Source
Active, not recruiting
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
NCT06671483· Phase 3· Takeda· Source
Active, not recruiting
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
NCT06846541· Phase 3· Alumis Inc· Source
Recruiting
A Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients With Active Psoriatic Arthritis
NCT06454188· Phase 4· CARE ARTHRITIS LTD.· Source
Active, not recruiting
Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)
NCT06331312· Phase 3· Novartis Pharmaceuticals· Source
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome
NCT05946941· Phase 3· Bristol-Myers Squibb· Source
Recruiting
Efficacy and Safety of Deucravacitinib Compared with Placebo in Participants with Active SLE (POETYK SLE-1)
2022-500699-76-00· Phase 3· Bristol-Myers Squibb Services Unlimited Company· Source
Active, not recruiting
Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis
NCT04991116· Phase 3· Sun Pharmaceutical Industries Limited· Source
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus
NCT04963296· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease
NCT04929210· Phase 4· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs
NCT04908202· Phase 3· Bristol-Myers Squibb· Source
Active, not recruiting
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate
NCT02629159· Phase 3· AbbVie· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Closed trials
Completed
A randomised, double-blind, multicentre study comparing the efficacy, safety and immunogenicity of proposed Abatacept biosimilar (DRL_AB) with Orencia® administered by the intravenous route as an add-on to methotrexate in the treatment of patients with moderate to severe rheumatoid arthritis
2023-506664-14-00· Phase 3· Dr Reddy's Laboratories Limited· Source
Completed
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis
NCT06624228· Phase 3· UCB Biopharma SRL· Source
Completed
A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis
NCT06586112· Phase 3· Alumis Inc· Source
Completed
A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Rheumatoid Arthritis
2023-504564-42-00· Phase 2· Anaptysbio Inc.· Source
Completed
Safety and Efficacy of RHH646 for Knee Osteoarthritis
NCT05816395· Phase 2· Novartis Pharmaceuticals· Source
Completed
A Study of Peresolimab (LY3462817) in Adults Participants With Moderately-to-Severely Active Rheumatoid Arthritis
2022-501425-20-00· Phase 2· Eli Lilly & Co.· Source
Completed
Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR)
NCT05767034· Phase 3· Novartis Pharmaceuticals· Source
Completed
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Tildrakizumab in Anti-TNF Naive Subjects with Active Psoriatic Arthritis II (INSPIRE 2)
2024-512142-42-00· Phase 3· Sun Pharmaceutical Industries Limited· Source
Completed
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent
NCT04936308· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study of Guselkumab in Participants With Active Psoriatic Arthritis
NCT04882098· Phase 3· Janssen Research & Development, LLC· Source
Completed
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)
NCT04314544· Phase 3· Sun Pharmaceutical Industries Limited· Source
Completed
A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis
NCT03915964· Phase 4· Eli Lilly and Company· Source
Report an error